Russell Investments Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-110,683
| Closed | -$19M | – | 3174 |
|
|
2021
Q3 | $19M | Buy |
110,683
+23,523
| +27% | +$3.08M | 0.03% | 619 |
|
|
2021
Q2 | $10.9M | Buy |
87,160
+86,877
| +30,699% | +$11M | 0.02% | 890 |
|
|
2021
Q1 | $38K | Buy |
+283
| New | +$36.6K | ﹤0.01% | 3047 |
|
|
2020
Q3 | – | Sell |
-21,223
| Closed | -$2.02M | – | 3294 |
|
|
2020
Q2 | $2.02M | Sell |
21,223
-13,643
| -39% | -$1.32M | ﹤0.01% | 1624 |
|
|
2020
Q1 | $3.13M | Sell |
34,866
-15,049
| -30% | -$1.17M | 0.01% | 1222 |
|
|
2019
Q4 | $2.65M | Buy |
49,915
+2,076
| +4% | +$94.7K | ﹤0.01% | 1574 |
|
|
2019
Q3 | $1.89M | Buy |
47,839
+22,333
| +88% | +$969K | ﹤0.01% | 1711 |
|
|
2019
Q2 | $1.05M | Hold |
25,506
| – | – | ﹤0.01% | 1966 |
|
|
2019
Q1 | $1.19M | Buy |
25,506
+5,869
| +30% | +$258K | ﹤0.01% | 1976 |
|
|
2018
Q4 | $856K | Buy |
19,637
+12,620
| +180% | +$630K | ﹤0.01% | 2054 |
|
|
2018
Q3 | $401K | Buy |
7,017
+2,354
| +50% | +$116K | ﹤0.01% | 2487 |
|
|
2018
Q2 | $213K | Sell |
4,663
-1,800
| -28% | -$65.6K | ﹤0.01% | 2620 |
|
|
2018
Q1 | $253K | Buy |
6,463
+944
| +17% | +$40.1K | ﹤0.01% | 2628 |
|
|
2017
Q4 | $239K | Sell |
5,519
-41,165
| -88% | -$1.54M | ﹤0.01% | 2626 |
|
|
2017
Q3 | $1.74M | Buy |
46,684
+26,773
| +134% | +$929K | ﹤0.01% | 1865 |
|
|
2017
Q2 | $605K | Sell |
19,911
-7,939
| -29% | -$230K | ﹤0.01% | 2341 |
|
|
2017
Q1 | $737K | Buy |
27,850
+13,108
| +89% | +$345K | ﹤0.01% | 2263 |
|
|
2016
Q4 | $378K | Buy |
+14,742
| New | +$467K | ﹤0.01% | 2552 |
|
Russell Investments Group's XLRN Position: Q4 2021 in Review
Russell Investments Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 110,683 shares — an estimated $19M sold.
Russell Investments Group first reported a position in XLRN in Q4 2016 and held it in 18 quarters. The position peaked at $19M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Russell Investments Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Russell Investments Group sold 110,683 Acceleron Pharma shares in Q4 2021, an estimated $19M.
- Russell Investments Group first reported a position in Acceleron Pharma in Q4 2016 and held it in 18 quarters.
- Russell Investments Group's Acceleron Pharma position peaked at $19M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Russell Investments Group's 13F filing for Q4 2021, filed 21 Jan 2022.